Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health Inc (HIMS) delivers innovative telehealth solutions through its direct-to-consumer platform, connecting users with licensed professionals for personalized care, wellness products, and prescription services. This news hub provides investors and industry observers with essential updates about the company’s operational milestones and market developments.
Access real-time announcements including quarterly earnings reports, strategic partnerships, product expansions, and regulatory filings. Our curated collection ensures you stay informed about HIMS’ position in the competitive digital healthcare sector without needing to track multiple sources.
Key updates across these areas:
Financial Performance: Earnings calls and SEC filings
Service Innovations: New telehealth offerings and treatment categories
Strategic Growth: Partnerships and market expansion initiatives
Regulatory Compliance: FDA updates and healthcare policy impacts
Bookmark this page for streamlined access to verified HIMS developments. Combine these updates with our analysis tools on Stock Titan to monitor the company’s evolving role in reshaping accessible healthcare solutions.
Hims & Hers Health, Inc. (NYSE: HIMS) has launched its mobile app, enhancing access to modern healthcare for over 500,000 subscription members. The app offers features such as guided programs, 24/7 concierge support, and a curated member store. CEO Andrew Dudum highlighted this launch as a key step in reshaping healthcare experiences. Users can manage treatments, access medical experts, and engage in community Q&As directly through the app. This initiative aims to provide a supportive, holistic approach to health and wellness.
Hims & Hers Health has announced the launch of its hair loss solutions in collaboration with Walmart. This partnership will allow customers access to a variety of products like minoxidil solutions and shampoos in select Walmart stores and online. The products cater to a significant market, addressing hair loss experienced by 1 in 3 women and two-thirds of men by age 35. Hims & Hers aims to enhance its reach and accessibility, reinforcing its commitment to providing convenient health and wellness solutions to consumers.
Hims & Hers Health, Inc. (NYSE: HIMS) has announced key leadership changes to enhance its growth trajectory in the telehealth industry. Yemi Okupe, a finance veteran with experience at PayPal, eBay, and Uber, will assume the role of Chief Financial Officer on January 24, 2022. Dr. Patrick Carroll, the current Chief Medical Officer, is appointed to the Board of Directors. The company's strategic focus remains on transforming healthcare and wellness, reporting a 79% revenue growth to $74.2 million in Q3 2021, and expanding its market presence in underpenetrated sectors valued at $65 billion.
Hims & Hers Health (NYSE: HIMS) has launched two new prescription products targeting hair loss in women: Topical Finasteride & Minoxidil Spray and Oral Spironolactone. This development aims to address a common issue affecting 30 million women in the U.S. The topical spray combines clinically proven ingredients for easy application, while the oral pill is designed to slow shedding and promote regrowth. These offerings respond to an increasing demand for effective hair loss treatments, with internet searches for hair loss rising 8% over the past year.
Hims & Hers Health, Inc. has appointed Jay Spitzer as the new Senior Vice President of Investor Relations, bringing over a decade of experience from Walgreens Boots Alliance. The company reported 79% revenue growth to $74.2 million in Q3 2021, with a 95% increase in subscribers, now totaling 551,000. Additionally, partnerships with major brands such as Amazon and Uber were announced. Hims & Hers is set to launch a new mobile platform aimed at enhancing health services.
Hims & Hers Health has launched its largest on-demand delivery partnership with Uber Technologies, allowing customers to order personal care products via the Uber Eats app in 12 major U.S. cities, including Los Angeles and Miami. This initiative is expected to enhance accessibility to various health and wellness products, including sexual wellness and skincare items. The partnership is described as a game-changer by Hims & Hers COO Melissa Baird, aiming for further expansions in the future.
Hims & Hers Health has unveiled attractive holiday bundles featuring discounts on popular hair and skin products. Consumers can enjoy up to 30% off original prices, with products like the Hims Hair Gift Set priced at
Hims & Hers Health, Inc. (NYSE: HIMS) is expanding its market reach by launching an official store on Amazon. This new initiative aims to enhance product accessibility, offering a range of health and wellness products including supplements and sexual health items. CEO Andrew Dudum stated this move addresses increasing consumer demand and allows the company to connect with digitally savvy customers. Exclusive bundles will also be available, including popular personal care products. This development reflects Hims & Hers' strategy to broaden its customer base and capitalize on retail opportunities.
Hims & Hers Health has announced the launch of its new mobile app aimed at providing personalized health services to over 500,000 subscribers. The app will feature curated health programs, 24/7 concierge services, and access to both medical experts and a specially designed Member Store for health products. CEO Andrew Dudum emphasized the app as a pivotal step in reshaping healthcare access, promising to streamline the user experience akin to popular platforms like Spotify and Netflix. The app will be available on both iOS and Android in the coming weeks.
Hims & Hers Health reported a 79% year-over-year revenue increase for Q3 2021, totaling $74.2 million, surpassing guidance. The company achieved 551,000 member subscriptions, a 95% increase from the previous year. Despite strong growth, the net loss widened to $(15.9) million, compared to $(5.9) million in Q3 2020, and Adjusted EBITDA remained negative at $(9.8) million. The company expects revenue for Q4 2021 between $76 million and $78 million and a full-year revenue forecast of $263 million to $265 million.